Press Release

Sesen Bio to Host Conference Call to Review First Quarter 2019 Financial Results and Updated Preliminary Data from Phase 3 VISTA Trial

April 29, 2019 at 7:30 AM EDT

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Apr. 29, 2019-- Sesen Bio (Nasdaq:SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today announced that Company management will host a conference call and webcast on Monday, May 13, 2019 at 8:00 a.m. EDT to review operating results for the first quarter ended March 31, 2019 and updated, preliminary primary and new secondary endpoint data from the Phase 3 VISTA trial of Vicinium® for patients with high-risk non-muscle invasive bladder cancer who have been previously treated with bacillus Calmette-Guérin.

To participate in the conference call, please dial (844) 831-3025 (domestic) or (315) 625-6887 (international) and refer to conference ID 7176228. The webcast can be accessed in the Investor Relations section of the Company's website at The replay of the webcast will be available in the investor section of the Company’s website at for 60 days following the call.

About Sesen Bio
Sesen Bio, Inc. is a late-stage clinical company advancing targeted fusion protein therapeutics for the treatment of patients with cancer. The company’s lead program, Vicinium®, also known as VB4-845, is currently in a Phase 3 registration trial, the VISTA trial, for the treatment of high-risk, BCG un-responsive non-muscle invasive bladder cancer (NMIBC). Vicinium is a locally-administered targeted fusion protein composed of an anti-EPCAM antibody fragment tethered to a truncated form of Pseudomonas Exotoxin A for the treatment of high-risk NMIBC. For more information, please visit the company’s website at

Source: Sesen Bio, Inc.

Erin Clark, Executive Director, Strategic Planning & Investor Relations